유럽 연합 - 체코어 - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolismus aminokyselin, vrozené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

유럽 연합 - 체코어 - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - antihemoragika - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

유럽 연합 - 체코어 - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - jiné léky pro žluči terapie - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

heaton k.s., praha array - 4670 buprenorfin-hydrochlorid; 12409 dihydrÁt naloxon-hydrochloridu - sublingvální tableta - 2mg/0,5mg - buprenorfin, kombinace

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

heaton k.s., praha array - 4670 buprenorfin-hydrochlorid; 12409 dihydrÁt naloxon-hydrochloridu - sublingvální tableta - 8mg/2mg - buprenorfin, kombinace

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

heaton k.s., praha array - 4670 buprenorfin-hydrochlorid - sublingvální tableta - 2mg - buprenorfin

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

heaton k.s., praha array - 4670 buprenorfin-hydrochlorid - sublingvální tableta - 8mg - buprenorfin

유럽 연합 - 체코어 - EMA (European Medicines Agency)

l. molteni & c. dei fratelli alitti società di esercizio s.p.a. - buprenorfin hydrochlorid - poruchy související s opiáty - další léky na nervový systém - sixmo je indikován pro substituční léčbu závislosti na opiátech v klinicky stabilních dospělých pacientů, kteří vyžadují ne více než 8 mg/den sublingvální buprenorfin, v rámci lékařské, sociální a psychologické péče.

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

medochemie bohemia, spol. s r.o., praha array - 10413 dextromethorfan-hydrobromid - sirup - 1,5mg/ml - dextromethorfan

유럽 연합 - 체코어 - EMA (European Medicines Agency)

bayer ag - riociguat - hypertenze, plicní - antihypertenzíva pro plicní arteriální hypertenzi - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnost byla prokázána v pau populace, včetně etiologie idiopatické nebo dědičné pah nebo pah spojenou s onemocněním pojivové tkáně. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.